Sorry, you need to enable JavaScript to visit this website.

LORBRENA® (lorlatinib) Indications and Usage


LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on

  • crizotinib and at least one other ALK inhibitor for metastatic disease; or
  • alectinib as the first ALK inhibitor therapy for metastatic disease; or
  • ceritinib as the first ALK inhibitor therapy for metastatic disease.

This indication is approved under accelerated approval based on tumor response rate and duration of response [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event


Please enter your search term(s) for LORBRENA®